Ben Fidler
Senior Editor at BioPharma Dive
Senior Editor at Industry Dive
Biotech Journalist; Senior Editor, BioPharma Dive. Former Deputy Biotech Editor, Xconomy.
Articles
-
2 weeks ago |
biopharmadive.com | Ben Fidler
Elevation Oncology has agreed to be acquired by an investment firm focused on buying struggling biotechs and shutting them down. The cancer drug developer on Monday accepted a bid from Concentra Biosciences, a vehicle controlled by hedge fund Tang Capital Partners. Through the deal, Concentra will pay $0.36 in cash for each Elevation share.
-
2 weeks ago |
biopharmadive.com | Ben Fidler
Dive Brief:An experimental cholesterol-lowering pill from Merck & Co. succeeded in a pair of late-stage studies, the company said Monday. In one study, Merck’s drug, enlicitide, was tested against a placebo in people already taking statins and who have either an inherited condition that causes high cholesterol or are at risk of atherosclerosis.
-
3 weeks ago |
biopharmadive.com | Ben Fidler
Dive Brief:The Food and Drug Administration has awarded Sarepta Therapeutics a new kind of fast pass that could help speed the reviews of certain gene therapy applications it brings to the regulator in the future. The so-called platform technology designation issued to Sarepta is meant to streamline the development and evaluation process for gene therapies using a specific delivery tool, a viral vector dubbed rAAVrh74.
-
3 weeks ago |
biopharmadive.com | Ben Fidler
This audio is auto-generated. Please let us know if you have feedback. Dive Brief:An experimental medicine from Vera Therapeutics succeeded in a late-stage trial in a rare kidney disease, positioning the company to discuss an approval application with U.S. regulators in the near future. According to Vera, the drug, called atacicept, met its main goal in a Phase 3 trial in IgA nephropathy, a chronic condition that can lead to kidney failure.
-
4 weeks ago |
biopharmadive.com | Ben Fidler
Dive Brief:A dual-acting drug developed by Summit Therapeutics and Akeso delayed tumor progression in a Phase 3 lung cancer trial but didn’t extend survival, complicating its potential path to approval in the U.S.When administered alongside chemotherapy, the drug, known as ivonescimab, reduced the risk of death or disease progression by 48% compared to chemotherapy alone in patients whose non-small cell lung cancer has a mutation in a gene called EGFR.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 8K
- Tweets
- 7K
- DMs Open
- No
FDA meeting gives window into gene therapy field’s angst https://t.co/0wHWFMwXhC by @NedPagliarulo #GeneTherapy
Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update https://t.co/CRKcoPzv59 $VERA - 31% $OTSKY + 6% $RGNX $ARVN $VIGL $SGMT
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from #ASCO25 https://t.co/JHdRyds1Cy by @Lilah_Alvarado @ByJonGardner and @NedPagliarulo